Point prevalence (%) of SL and DP for patients with RA and a matched reference group from the general population, stratified by sex
| Days before and after treatment start | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| −360 | −270 | −180 | −90 | 0 | 90 | 180 | 270 | 360 | |||
| Women | Patients with RA (n=299) | SL | 24.7 | 26.1 | 31.4 | 32.8 | 39.8 | 32.4 | 29.8 | 29.1 | 30.8 |
| DP | 31.8 | 33.1 | 33.8 | 35.1 | 35.5 | 37.5 | 37.5 | 39.1 | 40.5 | ||
| Reference group (n=1196) | SL | 6.1 | 5.8 | 5.5 | 6.4 | 6.4 | 6.5 | 6.3 | 6.0 | 6.6 | |
| DP | 9.9 | 10.2 | 10.6 | 10.9 | 11.0 | 11.4 | 11.8 | 12.3 | 12.6 | ||
| Men | Patients with RA (n=66) | SL | 13.6 | 15.2 | 19.7 | 27.3 | 33.3 | 25.8 | 22.7 | 22.7 | 24.2 |
| DP | 27.3 | 27.3 | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | 28.8 | ||
| Reference group (n=264) | SL | 4.2 | 3.8 | 3.4 | 4.5 | 3.0 | 3.4 | 2.7 | 2.3 | 1.5 | |
| DP | 6.1 | 6.1 | 6.4 | 6.4 | 6.4 | 6.8 | 6.8 | 7.6 | 8.3 | ||
DP, disability pension; RA, rheumatoid arthritis; SL, sick leave.